VKTX
Viking Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website vikingtherapeutics.com
- Employees(FY) 23
- ISIN US92686J1060
Performance
-6.0%
1W
+5.44%
1M
+128.05%
3M
+639.78%
6M
+288.77%
YTD
+229.01%
1Y
Profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Investment Analysis Report: VKTX
Overview
VKTX is a pharmaceutical company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $3.64 billion. In this report, we will conduct a comprehensive analysis of VKTX's financial statements to evaluate its valuation, fin...
Technical Analysis of VKTX 2024-05-10
Overview:
In analyzing the technical indicators for VKTX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Indicators:
- Moving Averages (MA): The 5-day Moving Average (MA) has been consistently above the...
Recent News & Updates
- 2024-05-13 10:00
How Viking Therapeutics Stock Could 30x(Motley Fool)
- 2024-05-12 20:15
Is Viking Therapeutics the Best Biotech Stock for You?(Yahoo Finance)
- 2024-05-09 18:55
The 3 Best Russell 2000 Stocks to Buy in May 2024(Investorplace)
- 2024-05-08 01:22
- 2024-05-07 02:04
- 2024-05-06 09:10
- 2024-05-06 03:10
- 2024-05-03 03:05
- 2024-05-02 18:49
- 2024-05-01 11:59
- 2024-04-30 23:59
- 2024-04-28 10:30
Is Viking Therapeutics Incredibly Undervalued?(Motley Fool)
- 2024-04-27 21:07
Can This High-Flying Stock 10x in 10 Years?(Yahoo Finance)
- 2024-04-26 06:00
3 Biotech Stocks to Buy on the Dip: April 2024(InvestorPlace)
- 2024-04-25 20:15
- 2024-04-25 18:00
3 Biotech Stocks to Buy on the Dip: April 2024(Investorplace)
- 2024-04-25 10:30
3 Millionaire-Maker Biotech Stocks(Motley Fool)
- 2024-04-25 09:01
- 2024-04-25 07:37
Q1 2024 Viking Therapeutics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-04-25 03:20
- 2024-04-24 23:28
11 Oversold MidCap Stocks To Buy Now(Insidermonkey)
- 2024-04-24 17:37
- 2024-04-24 17:32
- 2024-04-24 16:05
- 2024-04-24 11:36
3 Biotech Stocks With Skyrocketing Potential: April 2024(InvestorPlace)
- 2024-04-24 08:57
- 2024-04-24 08:00
3 Red-Hot Biotech Rockets Blasting Off in 2024(InvestorPlace)
- 2024-04-24 05:50
- 2024-04-24 04:05
- 2024-04-23 16:43
Page 1 of 10
previousnext